<SEC-DOCUMENT>0001295345-17-000080.txt : 20170407
<SEC-HEADER>0001295345-17-000080.hdr.sgml : 20170407
<ACCEPTANCE-DATETIME>20170407120703
ACCESSION NUMBER:		0001295345-17-000080
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170407
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170407
DATE AS OF CHANGE:		20170407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emerald Medical Applications Corp.
		CENTRAL INDEX KEY:			0000797542
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				680080601
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15746
		FILM NUMBER:		17748510

	BUSINESS ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141
		BUSINESS PHONE:		97237444505

	MAIL ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19950916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INFERGENE CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mrla8k04072017.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<body>

<hr SIZE="4" NOSHADE COLOR="#000000">

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="4"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</b></font></p>

<p ALIGN="CENTER"><b><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="3">Washington, D.C.
20549<br>
</font></b></p>

<p ALIGN="CENTER"><font SIZE="4" FACE="Times New Roman, Times, Serif">___________________<br>
<br>
<strong>FORM 8-K<br>
</strong>___________________</font></p>

<p align="center"><font size="3"><b>CURRENT REPORT</b> </font></p>

<p align="center"><font size="2"><b>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934</b> </font></p>

<p align="center"><font size="2">Date of report (date of earliest event reported):
April 4, 2017</font></p>

<p align="center">&nbsp;</p>

<p ALIGN="CENTER"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="5"><b><u>
<font size="1">

<font size="5">E</font><font size="4">merald </font><font size="5">M</font><font size="4">edical </font><font size="5">
<font size="1" face="TIMES NEW ROMAN, TIMES, SERIF">

<font size="5">A</font><font size="4">pplications </font></font>C</font><font size="4">orp.</font></font></u><br>
</b></font><font face="TIMES NEW ROMAN, TIMES, SERIF" size="1">(Exact Name of Registrant
as Specified in its Charter)</font></p>

<p ALIGN="CENTER"><font size="2">Commission File No.: 0-15476</font></p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td width="50%" align="center" style="height: 1px"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>Delaware</u></font></td>
    <td width="50%" align="center" style="height: 1px"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>68-0080601</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(State of Incorporation)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(I.R.S. Employer
    Identification No.)</font></td>
  </tr>
  <tr>
    <td width="50%" align="center" style="height: 1px"><font size="1">&nbsp; </font></td>
    <td width="50%" align="center" style="height: 1px"><font size="1">&nbsp; </font></td>
  </tr>
  <tr>
    <td width="50%" align="center" style="height: 1px">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>7 Imber Street,
	Petach Tikva,
	Israel</u></font></td>
    <td width="50%" align="center" style="height: 1px">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>4951141</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(Address of Principal
    Executive Offices)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(ZIP Code)</font></td>
  </tr>
</table>

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">Registrant's
Telephone Number, including area code: (972) 3-744-4505</font></p>

<p><font size="2">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below): </font></p>

<p><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) <br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Soliciting material
pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</font></p>


<p Style='page-break-before:always'>

<hr SIZE="2" NOSHADE COLOR="#000000">

	<font size="2" FACE="Times New Roman">
<p align="justify"><b>Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.</b></p>
<p align="justify">On April 4, 2017, the Board of Directors of Emerald Medical
Applications Corp. (the &quot;Registrant&quot;) appointed Mr. Alimi Ahmed, who had been
serving as a director of the Registrant since December 25, 2016, as Chairman of
the Board of Directors, replacing Mr. Yair Fudim, who had served as Chairman
since April 30, 2015. Mr. Fudim will continue to serve as a Director.</p>
<p align="justify">Alimi Ahmed, age 47, who has served on the Registrant's Board
since December 30, 2016, as the Registrant's new CEO. Mr. Ahmed, is
highly-accomplished investor who has served in management of several early-stage
medical companies, including his current position as Chairman and CEO of VaxilBio Ltd, an Israeli-based company founded by scientists from the Weizmann
Institute, Israel's top research university, to provide new approaches to
immunotherapy. Mr. Ahmed is also an investor of Therapix Biosciences Ltd (&quot;Therapix
Bio&quot;). On March 21, 2017, the SEC declared Therapix Bio's registration statement
on Form F-1 effective, successfully registering 2,000,000 American Depositary
Shares, or ADSs, which are listed on the NASDAQ (NASDAQ: TRPX0 and on the
Tel-Aviv Stock Exchange (TASE: THXBY), at&nbsp;the public offering price&nbsp;of $6.00 per
ADS, which offering was underwritten by Laidlaw &amp; Company (UK) Ltd.</p>
<p align="justify">Mrs. Adi Zamir, the Registrant's CEO, submitted a letter to
the Board of Directors on March 26, 2017,announcing that pursuant to the terms
of her employment agreement, she would resign as the Registrant's CEO effective
on June 23, 2017 (the &quot;Effective Date&quot;). During the period from March 26, 2017
until the Effective Date, Mrs. Zamir stated that she will continue to serve as
CEO and further stated that if the Registrant appoints a successor CEO prior to
the Effective Date, Mrs. Zamir agreed to continue to serve the Registrant in a
non-executive officer capacity until the Effective Date.</p>
<p align="justify">The Registrant's Board of Directors accepted the letter of
resignation and is most appreciative of the professional services and diligence
exhibited by Mrs. Zamir in the performance of her duties as CEO to date and
through June 23, 2017. The letter of resignation dated March 26, 2017 is
attached as an Exhibit 17.7 hereto.</p>
<font size="2">

<p ALIGN="JUSTIFY"><strong>Item 9.01 Financial Statements and Exhibits.</strong></p>

<p ALIGN="JUSTIFY">(a) The following documents are filed as exhibits to
this report on Form 8-K or incorporated by reference herein. Any document incorporated by
reference is identified by a parenthetical reference to the SEC filing that included such
document.</p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%" height="0">
  <tr VALIGN="BOTTOM">
    <td height="0" width="8%"><p align="left"><font SIZE="2">Exhibit
    No.</font></td>
    <td height="0" width="92%"><font SIZE="2">Description</font></td>
  </tr>
  <tr>
    <td width="8%" height="0%"><font size="2">17.7</font></td>
    <td width="92%" height="0%"><font size="2">Letter of Resignation dated March 26,
	2017 (effective June 23, 2017), filed herewith.</td>
  </tr>
  <tr>
    <td width="8%" bgcolor="#FFFFFF" height="0%">&nbsp;</td>
    <td width="92%" bgcolor="#FFFFFF" height="0%">&nbsp;</td>
  </tr>
	</table>

	</font>

<p style="text-align: center"><font size="2" face="Times New Roman">
	<font size="2">SIGNATURES</font></p>

<p ALIGN="JUSTIFY"><font size="2">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%">
  <tr VALIGN="TOP" BGCOLOR="#66FFFF">
    <td ALIGN="LEFT" WIDTH="100%" bgcolor="#FFFFFF"><div
    STYLE="MARGIN-LEFT: 11px; TEXT-INDENT: -10px"><u><p><i><font
    face="TIMES NEW ROMAN, TIMES, SERIF" size="2">/s/ Alimi Ahmed</font></i></u><br>
    <font size="2">Chairman<br>
    	Alimi Ahmed<br>
    <i>&nbsp;&nbsp;</i>Date: April 7, 2017</font></p>
    </div></td>
  </tr>
</table>

	</font>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-17
<SEQUENCE>2
<FILENAME>exh17_7.htm
<DESCRIPTION>EXHIBIT 17.7
<TEXT>
<html>
<body>

<p><font size="2">EXHIBIT 17.7</font></p>
<p style="text-align: center"><font size="2">Adi Zamir</font><br style="font-size: x-small">
<font size="2">Letter of Resignation</font></p>
<p><font size="2">March 26, 2017</font><br style="font-size: x-small">
<br style="font-size: x-small"><font size="2">Board of Directors</font><br style="font-size: x-small">
<font size="2">Emerald Medical Applications Corp.</font><br style="font-size: x-small">
<font size="2">Attention: Yair Fudim, Chairman</font></p>
<p><font size="2">Please accept this letter as notice under my employment
agreement that effective June 23, 2017 (the &quot;Effective Date&quot;), I will cease
serving Chief Executive Officer of Emerald Medical Applications Corp. (the
&quot;Registrant&quot;) and its wholly-owned Israeli subsidiary, Emerald Medical
Applications Ltd.</font></p>
<p><font size="2">Until the Effective Date, I will continue to serve as Chief
Executive Officer and perform all of my duties as CEO to the best of my
abilities on behalf of the Registrant and Emerald Ltd. Furthermore, I will
assist the Board with the preparation and execution of a proper transition to
whomever the Board will select as the new CEO. If the Board shall appoint a new
CEO prior to June 23, 2017, I will continue to serve in a non-executive officer
capacity until the Effective Date.</font></p>
<p><font size="2">The reason for my resignation is to allow me to pursue other
business opportunities and I wish the Registrant and Emerald Ltd the very best
success for the future.</font><br style="font-size: x-small">
<br style="font-size: x-small"><font size="2">Respectfully yours,</font><br style="font-size: x-small">
<font size="2">/s/:<i> Adi Zamir</i></font><br style="font-size: x-small">
<font size="2">Adi Zamir</font></p>

</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
